FDA accepts Aquestive's Anaphylm NDA resubmission with March 2027 review date

October 15, 2026 7:00 AM

Aquestive Therapeutics (NASDAQ: AQST) announced that the U.S. Food and Drug Administration has accepted the company's resubmission of the New ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found